Discovery Therapeutics Caribe
Private Company
Funding information not available
Overview
Discovery Therapeutics Caribe is a private, late-stage biotech firm founded in 2015, targeting the significant unmet medical need in diabetic foot ulcer (DFU) care. The company's core asset is based on intralesional recombinant human Epidermal Growth Factor (rhEGF), a biologic approach designed to stimulate healing in complex wounds. Operating from San Juan, the company positions itself with global partners and is focused on navigating the clinical and regulatory pathway to bring this therapy to the American market. Its activities suggest a strategic effort to localize and develop an existing biologic candidate for a new, high-value geographic region.
Technology Platform
Intralesional administration of recombinant human Epidermal Growth Factor (rhEGF) for localized stimulation of wound healing.
Opportunities
Risk Factors
Competitive Landscape
The advanced wound care market includes competitors using other growth factors (e.g., Regranex/PDGF), skin substitutes, and cell-based therapies. DTC's intralesional rhEGF approach seeks to differentiate via direct, localized delivery. Its primary competition is the entrenched standard of care, which often leads to chronic wounds and amputations, representing a significant opportunity for any proven superior therapy.